Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Editas Medicine (Nasdaq: EDIT) announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress in Seville, Spain, Oct 7–10, 2025.
Presentation: “A transformative LDL‑cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non‑human primates.”
Presenter: Linda Burkly, Ph.D., Executive VP & Chief Scientific Officer. Session: Gene Editing II, Ex Vivo Applications on Thursday, Oct 9 at 5:00 p.m. CEST / 11:00 a.m. ET. Final Abstract No. OR069. Abstracts are available to registrants.
Management will also appear at two investor events in October: H.C. Wainwright Genetic Medicines Virtual Conference (fireside chat, Oct 14) and Chardan 9th Annual Genetic Medicines Conference panel (Oct 21, New York). Live webcasts and archived replays will be available in the company Investors section for about 30 days.
Editas Medicine (Nasdaq: EDIT) ha annunciato una presentazione orale al 32° Congresso Annuale ESGCT della European Society of Gene and Cell Therapy a Siviglia, Spagna, dal 7 al 10 ottobre 2025.
Presentazione: “Una medicina di editing genetico in vivo con CRISPR in grado di abbassare transformativo LDL‑colesterolo che funziona aumentando funzionalmente LDLR nei topi e nei primati non umani.”
Relatore: Linda Burkly, Ph.D., Vicepresidente Esecutivo e Direttore Scientifico. Sessione: Gene Editing II, Applicazioni Ex Vivo giovedì 9 ottobre alle 17:00 CEST / 11:00 ET. Numero astratto finale OR069. Gli abstract sono disponibili per i partecipanti registrati.
La direzione parteciperà anche a due eventi per investitori in ottobre: la conferenza virtuale di H.C. Wainwright Genetic Medicines (chat informale, 14 ottobre) e il panel della Chardan 9th Annual Genetic Medicines Conference (21 ottobre, New York). Le presentazioni in diretta e le repliche archiviate saranno disponibili nella sezione Investitori dell'azienda per circa 30 giorni.
Editas Medicine (Nasdaq: EDIT) anunció una presentación oral en el 32.º Congreso Anual de la Sociedad Europea de Terapia Génica y Celular (ESGCT) en Sevilla, España, del 7 al 10 de octubre de 2025.
Presentación: “Un medicamento de edición genética in vivo con CRISPR que transforma la reducción de LDL‑colesterol y que aumenta funcionalmente LDLR en ratones y primates no humanos.”
Ponente: Linda Burkly, Ph.D., Vicepresidenta Ejecutiva y Directora Científica. Sesión: Gene Editing II, Aplicaciones Ex Vivo el jueves 9 de octubre a las 17:00 CEST / 11:00 ET. Número del Resumen Final OR069. Los resúmenes están disponibles para los registrados.
La dirección también participará en dos eventos para inversionistas en octubre: la Conferencia Virtual de Medicina Genética de H.C. Wainwright (charla junto a fuego, 14 de octubre) y el panel de la Conferencia Anual de Medicinas Genéticas de Chardan (21 de octubre, Nueva York). Las presentaciones en directo y las repeticiones estarán disponibles en la sección de Inversores de la empresa durante unos 30 días.
Editas Medicine (나스닥: EDIT)는 2025년 10월 7일부터 10일까지 스페인 세비야에서 열리는 ESGCT(유럽 유전자 및 세포 치료학회) 32회 연례 Congress에서 구두 발표를 발표했습니다.
발표: “LDL‑콜레스테롤 저하를 위한 in vivo CRISPR 유전자 편집 의약품으로, 마우스와 비인간 영장류에서 LDLR를 기능적으로 상향 조절합니다.”
발표자: Linda Burkly, Ph.D., 최고 부사장 겸 최고과학책임자. 세션: Gene Editing II, Ex Vivo 응용 10월 9일 목요일 17:00 CEST / 11:00 ET. 최종 초록 번호 OR069. 초록은 등록자에게 제공됩니다.
경영진은 10월에 두 차례의 투자자 행사에도 참석합니다: H.C. Wainwright Genetic Medicines Virtual Conference(연설 대담, 10월 14일)와 Chardan 9th Annual Genetic Medicines Conference 패널(10월 21일, 뉴욕). 생방송과 archived 재방송은 회사의 투자자 섹션에서 약 30일간 제공됩니다.
Editas Medicine (NYSE: EDIT) a annoncé une présentation orale lors du 32e congrès annuel de la ESGCT (European Society of Gene and Cell Therapy) à Séville, Espagne, du 7 au 10 octobre 2025.
Présentation : « Un médicament d’édition génétique in vivo, utilisant CRISPR pour abaisser le LDL-cholestérol, qui réactive fonctionnellement LDLR chez la souris et chez les primates non humains. »
Intervenant : Linda Burkly, Ph.D., vice-présidente exécutive et directrice scientifique. Séance : Gene Editing II, Applications Ex Vivo, le jeudi 9 octobre à 17h00 CEST / 11h00 ET. Numéro du résumé final : OR069. Les résumés sont accessibles aux inscrits.
La direction participera également à deux événements réservés aux investisseurs en octobre : la conférence virtuelle sur les médicaments génétiques de H.C. Wainwright (conversation informelle, le 14 octobre) et la table ronde de la 9e Conférence annuelle sur les médicaments génétiques de Chardan (le 21 octobre, New York). Les diffusions en direct et les rediffusions seront disponibles dans la section Investisseurs du site de l’entreprise pendant environ 30 jours.
Editas Medicine (Nasdaq: EDIT) kündigte eine mündliche Präsentation auf dem 32. Jahreskongress der ESGCT (European Society of Gene and Cell Therapy) in Sevilla, Spanien, vom 7. bis 10. Oktober 2025 an.
Präsentation: „Ein transformierendes in vivo CRISPR-Geneditierungsmedikament zur Senkung des LDL-Cholesterins, das LDLR funktionell bei Mäusen und Nicht-Mebl-Primaten reguliert.“
Referentin: Linda Burkly, Ph.D., Executive VP & Chief Scientific Officer. Sitzung: Gene Editing II, Ex Vivo Anwendungen am Donnerstag, dem 9. Oktober um 17:00 Uhr CEST / 11:00 Uhr ET. Abstrakt-Nummer OR069. Abstracts stehen registrierten Teilnehmern zur Verfügung.
Das Management wird auch an zwei Investorenveranstaltungen im Oktober teilnehmen: der H.C. Wainwright Genetic Medicines Virtual Conference (fireside chat, 14. Oktober) und der Chardan 9th Annual Genetic Medicines Conference Panel (21. Oktober, New York). Live-Übertragungen und archivierte Wiederholungen stehen in der Investoren-Sektion des Unternehmens etwa 30 Tage lang zur Verfügung.
Editas Medicine (ناسداك: EDIT) أعلنت عن عرض شفهي في مؤتمر ESGCT الـ 32 للجمعية الأوروبية للعلاج الجيني والخليوي في إشبيلية، إسبانيا، في الفترة من 7 إلى 10 أكتوبر 2025.
العرض: “دواء تعديل جيني في الجسم الحي باستخدام CRISPR يخفض LDL‑كولسترول ويزيد وظيفياً LDLR في الفئران والقردة غير البشرية.”
المقدم/المقدمة: ليندا بوركللي، دكتوراه، نائب الرئيس التنفيذي وكبير مسؤولي العلم. الجلسة: Gene Editing II، تطبيقات Ex Vivo يوم الخميس 9 أكتوبر الساعة 5:00 مساءً بتوقيت وسط أوروبا الصيفي / 11:00 صباحاً بتوقيت شرق الولايات المتحدة. الملخص النهائي رقم OR069. يمكن للمشتركين الاطلاع على الملخصات.
سيحضر المدراء أيضاً حدثين للمستثمرين في أكتوبر: المؤتمر الافتراضي لأدوية جينية من H.C. Wainwright (جلسة حوارية، 14 أكتوبر) ومؤتمر تشاردن التاسع للأدوية الجينية (21 أكتوبر، نيويورك). ستتوفر البثوث المباشرة وإعادة التشغيل المحفوظة في قسم المستثمرون بالشركة لمدة نحو 30 يوماً.
Editas Medicine (纳斯达克：EDIT)宣布将在欧洲基因与细胞治疗学会（ESGCT）第32届年度大会于西班牙塞维利亚举行的会上进行口头报告，时间为2025年10月7日至10日。
报告：“一种在体 CRISPR 基因编辑药物，能够降低 LDL 胆固醇并在小鼠和非人灵长类动物中功能性上调 LDLR。”
报告人：Linda Burkly，博士，执行副总裁兼首席科学官。场次：Gene Editing II，体外应用，周四，10月9日，CEST 17:00 / ET 11:00。最终摘要编号 OR069。摘要对注册者开放。
管理层还将出席十月份的两场投资者活动：H.C. Wainwright Genetic Medicines Virtual Conference（炉边谈话，10月14日）以及 Chardan 第九届年度基因药物会议小组讨论（10月21日，纽约）。现场广播和存档回放将在公司 投资者 部分提供约30天。
- None.
- None.
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain.
- European Society of Gene and Cell Therapy (ESGCT) Congress
Title: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates
Session Date and Time: Thursday, October 9, 5:00 p.m. CEST / 11:00 a.m. ET
Session Title: 9A: Gene Editing II, Ex Vivo Applications
Room: Parallel A
Presenter: Linda Burkly, Ph.D, Executive Vice President and Chief Scientific Officer, Editas Medicine
Final Abstract Number: OR069
Abstracts are available to registrants on the ESGCT website. The oral presentation will also be posted to the “Posters & Presentations” section of the Company’s website at the time of the presentation and will remain accessible following the event.
In addition, management will participate in the following upcoming investor conferences in October:
- H.C. Wainwright Genetic Medicines Virtual Conference
Format: Fireside Chat
Date: Tuesday, October 14, 7:00 a.m. ET
Location: Virtual
- Chardan 9th Annual Genetic Medicines Conference
Panel Discussion: Genome Editing: Next Wave Technologies
Date: Tuesday, October 21, 8:45 a.m. ET
Location: New York, NY
To access a live webcast of the presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
When and where will Editas Medicine (EDIT) present at ESGCT 2025?
Who is presenting Editas Medicine’s abstract OR069 at ESGCT 2025?
What is the topic of Editas Medicine’s ESGCT presentation (EDIT)?
How can investors watch Editas Medicine (EDIT) presentations and replays?
What investor events will Editas management attend in October 2025?
